Literature DB >> 33720603

[Anti-viral activity of enisamium iodide against viruses of influenza and ARVI's on different cell lines].

V V Zarubaev1, A V Slita1, E O Sinegubova1, A A Muryleva1, I N Lavrentieva1.   

Abstract

Influenza and ARVI represent the most numerous and dangerous group of causative agents of respiratory infections human. AIM: Characterization of the antiviral properties of enisamium iodide against human respiratory viruses in in vitro experiments.
MATERIALS AND METHODS: In the course of experiments, the cytotoxic properties of enisamium iodide were studied against the cell lines Vero, MA-104, A549, L-41 and HEp-2. The antiviral activity of enisamium iodide was studied using virus yield reduction assay against influenza viruses, parainfluenza virus, respiratory syncytial virus, Coxsackie B3 and Coxsackie B4 viruses, as well as adenoviruses types 5 and 6.
RESULTS: The most sensitive to the action of enisamium iodide was the human parainfluenza virus, whose activity decreased by 2.3 orders of magnitude under the action of the drug in A549 cells. Of the cell cultures used, enisamium iodide exhibited the maximum antiviral effect in human lung carcinoma cells A549, where, in its presence, the level of reproduction of adenoviruses of types 5 and 6, Coxsackie viruses B3 and B4, and human parainfluenza virus decreased by an order of magnitude or more. The antiviral activity of enisamium iodide was least manifested in Vero cells.
CONCLUSION: According to the results of in vitro experiments, enisamium iodide can be considered as an antiviral drug with a wide spectrum of activity against human respiratory viruses.

Entities:  

Keywords:  ARVI; anti-viral activity; enisamium iodide; influenza; non-permissive cell lines

Year:  2020        PMID: 33720603     DOI: 10.26442/00403660.2020.11.000872

Source DB:  PubMed          Journal:  Ter Arkh        ISSN: 0040-3660            Impact factor:   0.467


  2 in total

1.  Enisamium Reduces Influenza Virus Shedding and Improves Patient Recovery by Inhibiting Viral RNA Polymerase Activity.

Authors:  Aartjan J W Te Velthuis; Tatiana G Zubkova; Megan Shaw; Andrew Mehle; David Boltz; Norbert Gmeinwieser; Holger Stammer; Jens Milde; Lutz Müller; Victor Margitich
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

2.  Enisamium Inhibits SARS-CoV-2 RNA Synthesis.

Authors:  Stefano Elli; Denisa Bojkova; Marco Bechtel; Thomas Vial; David Boltz; Miguel Muzzio; Xinjian Peng; Federico Sala; Cesare Cosentino; Andrew Goy; Marco Guerrini; Lutz Müller; Jindrich Cinatl; Victor Margitich; Aartjan J W Te Velthuis
Journal:  Biomedicines       Date:  2021-09-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.